Notice of Proposed Sale · 144
Ironwood Pharmaceuticals, Inc.
IRWDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- IRONWOOD PHARMACEUTICALS INC
- Issuer CIK
- 0001446847
- SEC file number
- 001-34620
- Phone
- 617-621-7722
- Person for whose account securities are to be sold
- Shetzline Michael
- Relationships to issuer
- Former Officer
- Street
- 100 SUMMER STREET, SUITE 2300
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02110
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Class A Common Stock | 83,306 | 377,376.18 | 165,239,947 | 09/24/2026 | Nasdaq | E Trade Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- E Trade Securities LLC
- Street
- 3 Edison Drive
- City
- Alpharetta
- State / country code
- GA
- Postal code
- 30005
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 03/08/2023 | Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 17,467 | N | 03/08/2023 | N/A |
| Class A Common Stock | 02/12/2024 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 13,606 | N | 02/12/2024 | N/A |
| Class A Common Stock | 02/12/2024 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 12,447 | N | 02/12/2024 | N/A |
| Class A Common Stock | 02/10/2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 33,333 | N | 02/10/2025 | N/A |
| Class A Common Stock | 02/10/2025 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 30,494 | N | 02/10/2025 | N/A |
| Class A Common Stock | 03/10/2026 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 34,153 | N | 03/10/2026 | N/A |
| Class A Common Stock | 03/10/2026 | Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan | Ironwood Pharmaceuticals, Inc. | 31,244 | N | 03/10/2026 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Shares sold to cover taxes from the vesting of stock awards granted by the Issuer.
Notice signature
- Notice date
- 09/23/2026
- Signed
- /s/ Michael Shetzline
Company context
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.